Showing results (51-60 of 163) with videos related to
Sort By:
Pageof 17
Arthritis and Rheumatism|March 29, 2002
Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndromeJohn P A Ioannidis, Vassilios A Vassiliou, Haralampos M MoutsopoulosMedicine|September 12, 2009
Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspectsEvangelia Baimpa, Issa J Dahabreh, Michael Voulgarelis, et al.Clinical Medicine (London, England)|September 16, 2020
Lessons of the month: Reemergence of rheumatic fever after a systemic streptococcal A infection: The role of cardiac MRI on the diagnosis of subclinical rheumatic carditisJohn Serelis, Nikolaos Alexopoulos, Fotini N Skopouli, et al.Arthritis and Rheumatism|January 31, 2002
Characterization of the cysteine-rich secretory protein 3 gene as an early-transcribed gene with a putative role in the pathophysiology of Sjögren's syndromeNikolaos I Tapinos, Mary Polihronis, George Thyphronitis, et al.The Journal of Rheumatology|April 19, 2011
Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritisKaterina Laskari, Athanasios G Tzioufas, Anna Antoniou, et al.Clinical Immunology (Orlando, Fla.)|September 19, 2017
Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndromeAdrianos Nezos, Ilir Cinoku, Clio P Mavragani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromesChristos I Maratheftis, Evangelos Andreakos, Haralampos M Moutsopoulos, et al.Arthritis Research & Therapy|November 10, 2010
Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective studyKaterina Laskari, Clio P Mavragani, Athanasios G Tzioufas, et al.Arthritis and Rheumatism|January 1, 2009
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodiesMaria G Tektonidou, Katerina Laskari, Demosthenes B Panagiotakos, et al.Journal of Autoimmunity|January 14, 2017
A comprehensive evaluation for the treatment of lupus nephritisEvangelia Zampeli, Dennis M Klinman, M Eric Gershwin, et al.Pageof 17